Compare UGP & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UGP | PCVX |
|---|---|---|
| Founded | 1937 | 2013 |
| Country | Brazil | United States |
| Employees | 11302 | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 6.1B |
| IPO Year | 2001 | 2020 |
| Metric | UGP | PCVX |
|---|---|---|
| Price | $5.35 | $52.99 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $5.05 | ★ $98.33 |
| AVG Volume (30 Days) | ★ 3.1M | 1.1M |
| Earning Date | 03-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.89% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.57 | N/A |
| Revenue Next Year | $5.90 | N/A |
| P/E Ratio | $9.99 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.71 | $28.09 |
| 52 Week High | $5.49 | $65.00 |
| Indicator | UGP | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 60.16 | 40.51 |
| Support Level | $3.71 | $51.34 |
| Resistance Level | N/A | $56.04 |
| Average True Range (ATR) | 0.15 | 2.23 |
| MACD | 0.03 | -0.46 |
| Stochastic Oscillator | 77.05 | 0.15 |
Ultrapar Participacoes SA engages in the investment of its own capital in services, commercial, and industrial activities, through the subscription or acquisition of shares of other companies. The company's business segments include: i) Ultragaz distributes LPG in the segments: bulk, comprising condominiums, trade, services, industries, and agribusiness; and bottled, mainly comprising residential consumers. ii) Ipiranga, the majority revenue generating segment, engages in the distribution and sale of oil-related products to service stations that operate under the Ipiranga brand throughout Brazil. iii) Ultracargo operates in specialized liquid bulk storage solutions in the main logistics centers. iv) Hidrovias: operates in logistics solutions and waterway and multimodal infrastructure.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.